Roberto Tozzi

Prof. Roberto Tozzi

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ICIlaria Cuccu
Ilaria Cuccu
FRFrancesco Raspagliesi
Francesco Raspagliesi
MMMario Malzoni
Mario Malzoni
EVEnrico Vizza
Enrico Vizza
APAndrea Papadia
Andrea Papadia
GBGiorgio Bogani
Giorgio Bogani

1 August 2015 in Gynecologic Oncology
Verified
Journal Article
Closed access
RTRoberto Tozzi
Roberto Tozzi
RGRaffaella Giannice
Raffaella Giannice
SCStefano Cianci
Stefano Cianci
STSarah Tardino
Sarah Tardino
RCRiccardo Garruto Campanile
Riccardo Garruto Campanile
HMHooman Soleymani Majd
Hooman Soleymani Majd

30 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
GSGiulia Spagnol
Giulia Spagnol
FSFrancesca Sensi
Francesca Sensi
OTOrazio De Tommasi
Orazio De Tommasi
MMMatteo Marchetti
Matteo Marchetti
GBGiulio Bonaldo
Giulio Bonaldo
CSCarlo Saccardi
Carlo Saccardi
Ovarian cancer (OC) has the highest mortality rate of all gynecological malignancies due to the high prevalence of advanced stages of diagnosis and the high rate of recurrence. Furthermore, the heterogeneity of OC tumors contributes to the rapid development of resistance to conventional chemotherapy. In recent years, in order to overcome these problems, targeted therapies have been introduced in various types of tumors, including gynecological cancer. However, the lack of predictive biomarkers showing different clinical benefits limits the effectiveness of these therapies. This requires the development of preclinical models that can replicate the histological and molecular characteristics of OC subtypes. In this scenario, organoids become an important preclinical model for personalized medicine. In fact, patient-derived organoids (PDO) recapture tumor heterogeneity with the possibility of performing drug screening. However, to best reproduce the patient’s characteristics, it is necessary to develop a specific extracellular matrix (ECM) and introduce a tumor microenvironment (TME), which both represent an actual object of study to improve drug screening, particularly when used in targeted therapy and immunotherapy to guide therapeutic decisions. In this review, we summarize the current state of the art for the screening of PDOs, ECM, TME, and drugs in the setting of OC, as well as discussing the clinical implications and future perspectives for the research of OC organoids.

1 March 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
HMHooman Soleymani Majd
Hooman Soleymani Majd
FFFederico Ferrari
Federico Ferrari
SMSanjiv Manek
Sanjiv Manek
KGKumar Gubbala
Kumar Gubbala
RCRiccardo Garruto Campanile
Riccardo Garruto Campanile
RTRoberto Tozzi
Roberto Tozzi

Verified
Journal Article
Open access
PDF file
Marco NoventaMarco Noventa
Marco Noventa
GSGiulia Spagnol
Giulia Spagnol
MMMatteo Marchetti
Matteo Marchetti
CSCarlo Saccardi
Carlo Saccardi
GBGiulio Bonaldo
Giulio Bonaldo
Amerigo VitaglianoAmerigo Vitagliano
Amerigo Vitagliano
Objective: we performed a systematic review/meta-analysis to evaluate the impact of septate uterus and hysteroscopic metroplasty on pregnancy rate-(PR), live birth rate-(LBR), spontaneous abortion-(SA) and preterm labor (PL) in infertile/recurrent miscarriage-(RM) patients. Data sources: a literature search of relevant papers was conducted using electronic bibliographic databases (Medline, Scopus, Embase, Science direct). Study eligibility criteria: we included in this meta-analysis all types of observational studies that evaluated the clinical impact of the uterine septum and its resection (hysteroscopic metroplasty) on reproductive and obstetrics outcomes. The population included were patients with a diagnosis of infertility or recurrent pregnancy loss. Study appraisal and synthesis methods: outcomes were evaluated according to three subgroups: (i) Women with untreated uterine septum versus women without septum (controls); (ii) Women with treated uterine septum versus women with untreated septum (controls); (iii) Women before and after septum removal. Odds ratios (OR) with 95% confidence intervals (CI) were calculated for the outcome measures. A p-value < 0.05 was considered statistically significant. Subgroup analysis was performed according to the depth of the septum. Sources of heterogeneity were explored by meta-regression analysis according to specific features: assisted reproductive technology/spontaneous conception, study design and quality of papers included Results: data from 38 studies were extracted. (i) septum versus no septum: a lower PR and LBR were associated with septate uterus vs. controls (OR 0.45, 95% CI 0.27–0.76; p < 0.0001; and OR 0.21, 95% CI 0.12–0.39; p < 0.0001); a higher proportion of SA and PL was associated with septate uterus vs. controls (OR 4.29, 95% CI 2.90–6.36; p < 0.0001; OR 2.56, 95% CI 1.52–4.31; p = 0.0004). (ii) treated versus untreated septum: PR and PL were not different in removed vs. unremoved septum(OR 1.10, 95% CI 0.49–2.49; p = 0.82 and OR 0.81, 95% CI 0.35–1.86; p = 0.62); a lower proportion of SA was associated with removed vs. unremoved septum (OR 0.47, 95% CI 0.21–1.04; p = 0.001); (iii) before-after septum removal: the proportion of LBR was higher after the removal of septum (OR 49.58, 95% CI 29.93–82.13; p < 0.0001) and the proportion of SA and PL was lower after the removal of the septum (OR 0.02, 95% CI 0.02–0.04; p < 0.000 and OR 0.05, 95% CI 0.03–0.08; p < 0.0001) Conclusions: the results show the detrimental effect of the uterine septum on PR, LBR, SA and PL. Its treatment reduces the rate of SA.

1 October 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
RTRoberto Tozzi
Roberto Tozzi
ZTZoe Traill
Zoe Traill
RCRiccardo Garruto Campanile
Riccardo Garruto Campanile
FFFederico Ferrari
Federico Ferrari
HMHooman Soleymani Majd
Hooman Soleymani Majd
KGKumar Gubbala
Kumar Gubbala